Loading clinical trials...
Loading clinical trials...
The goal of this clinical trial is to explore the value of molecular residual disease (MRD) monitoring based on ctDNA in borderline resectable or locally advanced pancreatic cancer. The main questions...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Peking Union Medical College Hospital
NCT06678659 · Unresectable, Locally Advanced, and more
NCT07300150 · Colorectal Cancer, Pancreatic Cancer, and more
NCT06307548 · Locally Advanced Colorectal Carcinoma, Recurrent Colorectal Carcinoma, and more
NCT06160323 · Pancreatic Cancer Non-resectable, Tumor Pancreas, and more
NCT07335497 · Locally Advanced / Metastatic Solid Tumors
Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions